The abstract is read at the publisher; the summary is JClub's.
Low Glul expression in CTNNB1-mutated hepatocellular carcinoma is linked to poor patient survival, highlighting glutamine synthetase as a key metabolic marker in this HCC subtype.
- Why it matters: β-catenin-mutant HCCs are molecularly distinct and often show tumor-wide GS and mTOR activation, but it is unclear how GS loss reshapes tumor–macrophage metabolism and disease outcome.
- What they did: TCGA analyses related CTNNB1-mutated HCC Glul expression to survival, and mice with hepatocyte and/or macrophage Glul deletion were tested in tumors co-expressing mutant CTNNB1 (T41A) and mutant Nrf2, with macrophage depletion using clodronate and single-cell spatial transcriptomics.
- The result: GS loss in β-catenin-mutant tumors is associated with aggressive disease via altered glutamate/glutamine availability, macrophage Glul upregulation, mTOR activation, and a shift from immunosurveillance to immunosuppression; clodronate or macrophage Glul deletion reduced tumor burden and improved survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.